Skip to main content

Dark Horse Consulting Group Acquires Converge Consulting

Written by Customer Service on . Posted in Mergers And Acquisitions.

WALNUT CREEK, Calif. and CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) — Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational consulting in advanced therapies—specifically the fields of cell and gene therapy (“CGT”) and biotherapeutics—is delighted to announce the acquisition of Converge Consulting, LLC (Converge). Converge is known for its ability to bridge the gap between sound strategy and reliable execution for biopharmaceutical organizations in the areas of supply chain, manufacturing, commercial launch readiness, operational excellence, enterprise IT solutions, CMC, and Quality.

With offices located in North America, Europe, and APAC, DHCG is a fully integrated global consulting practice offering a range of strategic and operational services to biopharma markets. Expanding on DHCG’s 2024 acquisition of BioTechLogic, Inc., this transaction demonstrates the Group’s continuing dedication to building a comprehensive ecosystem of integrated offerings across advanced therapies.

“Adding Converge to Dark Horse Consulting Group continues to extend our ability to support clients throughout the entire product development lifecycle,” said Anthony Davies, DHCG Founder and CEO. “Converge will further expand our Group’s shared capabilities into clinical and commercial supply chain, commercial launch, and enterprise IT solution support, while also broadening our expertise in CMC and Quality.”

“The opportunity to join DHCG is a clear win for our team and for our clients as well,” said Todd Applebaum, Converge Consulting’s Managing Director and Co-Founder. “We look forward to expanding our offerings for current Converge clients, building on what DHCG already provides, and introducing new services based on our combined capabilities and expertise.”

Pharus served as exclusive advisor to Converge on the transaction and Foley Hoag LLP acted as counsel to the company. DHCG was represented by Fenwick & West LLP.

About Dark Horse Consulting Group

Dark Horse Consulting Group, a global company with offices in the U.S., U.K., and Singapore, was founded in 2014 with the purpose of accelerating cell and gene therapies through unmatched consulting expertise. The Group comprises three business units: DHC, BioTechLogic, and now Converge Consulting. The DHCG consulting team’s unrivalled collective knowledge spans development, manufacturing, compliance, quality, regulatory, modeling, and business strategy, addressing a diverse range of client needs.

About Converge Consulting

Converge Consulting serves the Life Sciences industry with strategy, operations, and execution expertise, collaborating with biotech, pharmaceutical, and CGT companies to achieve important business objectives. Operating out of Massachusetts’ Boston/Cambridge life science hub, Converge’s approach focuses on bridging the gap between sound strategy and reliable execution.

CONTACT: Media inquiries:
contactus@darkhorseconsultinggroup.com
+1 (408)-326 0303 Ext. 100

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.